WO2005095350A1 - Pyrazole compounds and uses related thereto - Google Patents

Pyrazole compounds and uses related thereto Download PDF

Info

Publication number
WO2005095350A1
WO2005095350A1 PCT/US2005/009292 US2005009292W WO2005095350A1 WO 2005095350 A1 WO2005095350 A1 WO 2005095350A1 US 2005009292 W US2005009292 W US 2005009292W WO 2005095350 A1 WO2005095350 A1 WO 2005095350A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
independently
alkoxy
hydrogen atom
Prior art date
Application number
PCT/US2005/009292
Other languages
French (fr)
Inventor
Hiroyuki Goto
Makoto Kakutani
Jun Nishiu
Yasuhiro Ohe
Jay P. Powers
Shinji Yata
Hua Tu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to AU2005228856A priority Critical patent/AU2005228856C1/en
Priority to CA002559945A priority patent/CA2559945A1/en
Priority to MXPA06010879A priority patent/MXPA06010879A/en
Priority to EP05733131A priority patent/EP1735282A4/en
Priority to JP2007505053A priority patent/JP2007530549A/en
Publication of WO2005095350A1 publication Critical patent/WO2005095350A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention relates to pyrazole compounds having HSDl inhibitory activity.
  • 11-Beta-hydroxysteroid dehydrogenase 1 (hereinafter, "110-HSD1" or “HSDl”) catalyzes the interconversion of glucocorticoids (hereinafter, "GC") between inert 11-keto forms (e.g. cortisone, 11-dehydrocorticosterone) and active 11/3-hydroxy forms (e.g. cortisol, corticosterone, respectively).
  • GC glucocorticoids
  • the enzyme in vivo, prefers the reductase direction from 11- keto to 11/5 -hydroxy, in other words, the production of active GC.
  • 11/3-HSD1 is ubiquitously expressed, most notably in liver, lung, adipose tissue, vasculature, ovary and the central nervous system.
  • the active GC is known to stimulate gluconeogenic enzymes and have effects at least in part in inducing hyperglycemia.
  • HSDl can be a second source of GC production in addition to the adrenal glands.
  • HSDl activity which causes an increase in local concentration of the active form and further expansion of adipose tissue. Such an action of HSDl should be critical in pathogenesis of obesity.
  • Diabetes mellitus the main feature of which disease is chronic hyperglycemia, introduces various metabolic abnormalities and shows symptoms of thirst, polydipsia, polyuria, and so on based on high glucose concentration.
  • a continuing hyperglycemic state can also lead to diabetic complications such as retinopathy, nephropathy, neuropathy, and myocardial and/or cerebral infarction by reason of arteriosclerosis.
  • Obesity is defined as a state of fatness coinciding with any disease that would be improved or not be progressed in case of weight decrease (e.g. diabetes, hyperlipidemia, hypertension) or with an excessive amount of fat in viscera. It is considered that, if such a state should continue, at least two of diabetes, hyperlipidemia, hypertension and related disorders would concur, followed by the onset of myocardial and/or cerebral infarction by reason of arteriosclerosis.
  • WO 03/104207 and WO 03/104208 disclose triazole compounds of the following general formula:
  • a and B are taken separately or together;
  • A is halo, unsubstituted or substituted C ⁇ - 6 alkyl, unsubstituted or substituted OC ⁇ - 6 alkyl or unsubstituted or substituted phenyl and B is -H, halo, unsubstituted or substituted Ci- ⁇ alkyl, unsubstituted or substituted OC ⁇ -6alkyl, unsubstituted or substituted -S - ⁇ alkyl, unsubstituted or substituted C 2 - 6 alkenyl, unsubstituted or substituted phenyl or unsubstituted or substituted naphthyl; and
  • each R 1 is -H, -OH, halo, unsubstituted or substituted .ioalkyl, unsubstituted or substituted C ⁇ - 6 alkoxy or unsubstituted or substituted C6.
  • aryl, or two R 1 taken together are a fused C 5 . 6 alkyl (either unsubstituted or substituted) or unsubstituted or substituted aryl ring;
  • R 2 and R 3 are taken separately or together;
  • R 2 is C1.-.4 alkyl (either unsubstituted or substituted), unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, either unsubstituted or substituted C 2 -_ 0 alkenyl, -CH 2 CO 2 H, -CH 2 CO 2 C ⁇ - 6 alkyl, -CH 2 C(O)NHR a , -NH 2 , -NHR a or N(R a ) and R 3 is unsubstituted or substituted Ci ⁇ a-kyl, unsubstituted or substituted C 2 - 10 alkenyl, unsubstituted or substituted SC ⁇ - 6 alkyl, unsubstituted or substituted C ⁇ -ioaryl, unsubstituted or substituted heterocyclyl or unsubstituted or substituted heteroaryl;
  • R a is unsubstituted or substituted C_- 3 alkyl, unsubstituted or substituted OC ⁇ - 3 alkyl, unsubstituted or substituted C 6 - ⁇ 0 ArC ⁇ - 6 alkylene or unsubstituted or substituted phenyl;
  • the compounds of the present invention improve physicochemical (stability, etc.) and biological (activity to inhibit HSDl, specificity, bioavailability, metabolism, etc.) profiles, as a result of the selection of structural characteristics as disclosed herein.
  • pyrazole compounds represented by the following formula have superior HSDl inhibitory activity, and are useful as HSDl inhibitors or therapeutic drugs for the treatment of diabetes or obesity.
  • the present invention provides the following:
  • the present invention provides pyrazole compounds represented by the following formula:
  • R 1 is a hydrogen atom, -CO-O-alkyl, -COOH, an alkyl group, an alkoxy group or a cycloalkyl group, wherein the alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R 10 )(R n ), -N(R 10 )-CO-R ⁇ , an aryl group and a heteroaryl group, wherein R 10 and R 11 are each independently a hydrogen atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom,
  • R 2 , R 3 , R 4 and R 5 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a cycloalkyl group or R 2 and R 3 , and/or R 4 and R 5 in combination with the carbon atoms to which they are attached form a ring represented by
  • Y 1 ring is a cycloalkane or a heterocycloalkane group
  • the wavy lines indicate the point of attachment to the remainder of the molecule
  • the cycloalkane group and the heterocycloalkane group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH ) h -OH, -N(R 12 )(R 13 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 , an aryl group and a heteroaryl group (h, R 12 , R 13 and R 14 are as defined above),
  • alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R 10 )(R n ), an aryl group and a heteroaryl group [0035] wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH, -N(R 12 )(R 13 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO
  • n is an integer of from 0 to 3;
  • Ar 1 is an aryl group or a heteroaryl group
  • R 6 and R 7 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )j-OH, -N(R 12 )(R 13 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 , an aryl group or heteroaryl group, wherein j is 0-3, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH, -N(R 12 )(R 13 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 , an aryl group and a heteroary
  • m is an integer of from 0 to 3 ;
  • R 8 and R 9 are each independently a hydrogen atom, a halogen atom, -OH, -NO 2 , -CN, an alkyl group, an alkoxy group, -CO-R 17 , -SO 2 -R 17 , -CO-N(R 18 )(R 19 ), -N(R 20 )(R 21 ) or in combination form -O-alkylene-O-, wherein the alkyl group and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R 10 )(R ⁇ ), -N(R 10 )-CO-R ⁇ , an aryl group and a heteroaryl group, wherein
  • R 17 is -OH, an alkoxy group, an alkyl group, -NH 2 , -NH-alkyl or -N(-alkyl) 2 , wherein the alkoxy group and alkyl groups are optionally substituted by substituents each independently selected from -OH, -SO 2 -R 22 and -(CH 2 ) t -CO-R 23 , wherein t is 0-3, R 22 is an alkyl group or -NH 2 , and R 23 is an alkyl group, -NH-alkyl, -N(-alkyl) 2 , or -NH 2 , wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 ) U -N(R 24 )(R 25 ), wherein u is 0-3, and R 24 and R 25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl,
  • R 18 and R 19 are each independently a hydrogen atom, an alkyl group or -(CH 2 ) P -R 26 , wherein p is 0-3 and R 26 is -OH, a haloalkyl group, an alkoxy group, -CO-NH 2 or -N(R 4 )(R 25 ), wherein R 24 and R 25 are as defined above;
  • R 20 and R 21 are each independently a hydrogen atom, an alkyl group -CO-R 23 or in combination with the nitrogen atom to which each is attached, form
  • alkyl group is optionally substituted by substituents each independently selected from -OH, -SO 2 -R 22 and -(CH 2 ) r CO-R 23 (wherein R 22 and R 23 are as defined above),
  • X 1 is -CO-, -CH 2 - or -CH 2 -CH 2 -, X 2 is -O-, -(CH 2 ) q - or -N(R 29 )- or a spirocyclic ring represented by
  • R 29 is a hydrogen atom, -CO-R 30 , -SO 2 -R 30 or -(CH 2 ) r -Ar 3 , wherein R 30 is an alkyl group, an alkoxy group, -NH-alkyl or -N(-alkyl) 2 , r is 0-3, and Ar 3 is an aryl group or heteroaryl group, wherein the aryl group and heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH, -N(R 12 )(R 13 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 , an aryl group and a heteroaryl group (h, R 12 , R 13 and R 14 are as defined above
  • Ar 2 is an aryl group, a heteroaryl group or a ring having the formula wherein N 1 is CH or ⁇ , X 3 is -(CH 2 ) v - 5 wherein v is 0-2, and W 1 is -C(R 31 )(R 32 )-, -CO- or - ⁇ (R 33 )-, wherein R 31 and R 32 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, -(CH 2 ) w -OH, -CO-R 34 , -L !
  • R 34 is -OH, an alkoxy group, an alkyl group or -N(R 37 )(R 38 ), wherein R 37 and R 38 are each independently a hydrogen atom, an alkyl group, -(CH 2 ) x -OH or an alkoxy group, wherein x is 0-3, L 1 is -(CH 2 ) y -, -O- or -CO-, wherein y is 0-3,
  • Ar 4 is an aryl group or a heteroaryl group, wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH, -N(R 12 )(R 13 ), -CN, -NO 2 , an alkoxy group, a
  • R 33 is a hydrogen atom, -CO-R 28 , -SO 2 -R 28 or -(CH 2 ) k -Ar 3 , wherein k is 0-3 (R 28 and Ar 3 are as defined above);
  • any variable used to define another variable is meant to have its most complete meaning as provided above, unless otherwise stated. Additionally, when a letter subscript is provided with a range (e.g., x and y being 0 to 3), the lower limit (0) is meant to indicate the presence of a bond. [0048] In some embodiments, the pyrazole compound has the formula above, wherein the subscript m is 0, a prodrug thereof or a pharmaceutically acceptable salt thereof.
  • the pyrazole compound has the formula above, wherein the subscript m is 0, and where R and R are in combination with the carbon atom to which they are attached to form
  • Y 1 ring is a C 3 . 8 cycloalkane group, and the compounds further include a prodrug thereof or a pharmaceutically acceptable salt thereof.
  • Ar 1 is an phenyl group. Still further preferred are those embodiments in which R 6 and R 7 are each independently a halogen atom or a hydrogen atom.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising one or more of the pyrazole compounds described above, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention provides a HSDl (11/3-hydroxysteroid dehydrogenase 1) inhibitor comprising a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
  • the present invention provides a therapeutic or prophylactic drug for diabetes, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
  • the present invention provides a therapeutic or prophylactic drug for obesity, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
  • the present invention provides a therapeutic or prophylactic drug for metabolic syndrome, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
  • the present invention provides a method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of a pyrazole compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
  • the present invention provides a method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of a pyrazole compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
  • the present invention provides a method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of a pyrazole compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
  • a therapeutic regimen comprises the use of a pyrazole compound as described above, in combination with a different therapeutic drug for the treatment of diabetes.
  • the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an c--glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer.
  • the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
  • pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
  • a therapeutic regimen comprises the use of a pyrazole compound as described above for obesity, which is used in combination with a different therapeutic drug for the treatment of diabetes.
  • the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an ⁇ -glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer.
  • the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
  • a therapeutic regimen comprises the use of a pyrazole compound as described above for metabolic syndrome, which is used in combination with a different therapeutic drug for the treatment of diabetes.
  • the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an ⁇ -glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer.
  • the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
  • pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
  • a therapeutic regimen comprises the use of a pyrazole compound as described above for diabetes, which is used in combination with a different therapeutic drug for the treatment of obesity.
  • the different therapeutic drug for obesity is Mazindol.
  • a therapeutic regimen comprises the use of a pyrazole compound as described above for obesity, which is used in combination with a different therapeutic drug for the treatment of obesity.
  • the different therapeutic drug for obesity is Mazindol.
  • a therapeutic regimen comprises the use of a pyrazole compound as described above for metabolic syndrome, which is used in combination with a different therapeutic drug for the treatment of obesity.
  • the different therapeutic drug for obesity is Mazindol.
  • alkyl group means a straight chain or branched chain alkyl group. Examples thereof include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group, 1-ethylpropyl group, hexyl group and the like. It is preferably a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.
  • cycloalkyl group means a saturated cyclic alkyl group. Examples thereof include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group and the like. It is preferably a cycloalkyl group having 3 to 8, more preferably 3 to 6, carbon atoms.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 27 , R 28 , Y 1 and Y 2 preferred are cyclopropyl, cyclobutyl and cyclopentyl, and particularly preferred is cyclopropyl.
  • Y 1 and Y 2 the rings are attached in a spirocyclic manner to the remainder of the molecule.
  • heterocycloalkyl group means a saturated 5- to 7-membered heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom.
  • heterocycloalkyl group examples thereof include tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, pyrazolidinyl group, imidazolidinyl group, oxazolidinyl group, thiazolidinyl group, tetrahydropyranyl group, dioxolanyl group, dioxanyl group, piperidinyl group, piperazinyl group, morpholinyl group and the like.
  • piperidinyl which in the case of the Y ring is attached in a spirocyclic manner to the remainder of the molecule.
  • alkenyl group means a straight chain or branched chain alkenyl group. Examples thereof include vinyl group, 1-propenyl group, allyl group, l-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 2-pentenyl group, 1-hexenyl group, 2-hexenyl group and the like. It is preferably a straight chain or branched chain alkenyl group having 2 to 6, more preferably 2 to 4, carbon atoms.
  • R 6 , R 7 , R 27 and R 28 preferred is vinyl.
  • the "aryl group” means an aromatic hydrocarbon group. Examples thereof include phenyl group, naphthyl group, anthryl group and the like. It is preferably a phenyl group or naphthyl group.
  • R 6 , R 7 , R 27 , R 28 , Ar 1 , Ar 2 , Ar 3 and Ar 4 preferred are phenyl and naphthyl, and particularly preferred is phenyl.
  • the "heteroaryl group” means a monocyclic or fused 5- to 14-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom.
  • Examples thereof include furyl group, thienyl group, pyrrolyl group, oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzoxazolyl group, indolizinyl group, quinolyl group, isoquinolyl group, quinazolinyl group, cinnolinyl
  • It is preferably a monocyclic or fused 5- to 10-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which includes furyl group, thienyl group, pyrrolyl group, oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzooxazolyl group and the like.
  • R 6 , R 7 , Ar 1 preferred are thienyl, pyrrolyl and pyridyl.
  • R 27 , R 28 , Ar 2 preferred are thienyl, pyrrolyl, oxazolyl, isooxazolyl, thiazolyl, imidazolyl, pyrazolyl and pyridyl, and particularly preferred are thienyl and pyridyl.
  • halogen atom means fluorine atom, chlorine atom, bromine atom or iodine atom. It is preferably fluorine atom or chlorine atom.
  • R 6 and R 7 preferred is fluorine atom or chlorine atom.
  • Ar 1 is particularly preferably phenyl, where only the 4-position of the phenyl is substituted by fluorine atom or chlorine atom.
  • R 8 and R 9 preferred is chlorine atom.
  • Ar 2 is particularly preferably phenyl, where at least the 2-position of the phenyl is substituted by chlorine atom.
  • R 27 and R 28 preferred are fluorine atom or chlorine atom.
  • haloalkyl group means a haloalkyl group wherein the above-defined “alkyl group” is substituted by the above-defined "halogen atom".
  • examples thereof include fluoromethyl group, difluoromethyl group, trifluoromethyl group, bromomethyl group, chloromethyl group, 1,2-dichloroethyl group, 2,2-dichloroethyl group, 2,2,2-trifluoroethyl group and the like. It is preferably a straight chain or branched chain haloalkyl group having 1 to 6, more preferably 1 to 4, carbon atoms, particularly preferably a trifluoromethyl group.
  • R 6 , R 7 , R 26 , R 27 , R 28 , R 31 and R 32 preferred are fluoromethyl group, difluoromethyl group or trifluoromethyl group.
  • alkoxy group means a straight chain or branched chain alkoxy group. Examples thereof include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, tert-butoxy group, pentyloxy group, hexyloxy group and the like. It is preferably a straight chain or branched chain alkoxy group having 1 to 6, more preferably 1 to 4, carbon atoms.
  • the "-CO-alkyl” means an alkylcarbonyl group having the above-defined "alkyl group” as the alkyl moiety. Examples thereof include acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, pentanoyl group, hexanoyl group and the like. It is preferably an alkylcarbonyl group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms. [0089] For R 12 , R 13 , R 24 , R 25 , R 35 and R 36 , particularly preferred are acetyl, propionyl, butyryl and isobutyryl.
  • the "-CO-O-alkyl” means an alkoxycarbonyl group having the above-defined "alkyl group” as the alkyl moiety. Examples thereof include methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, sec-butoxycarbonyl group, tert-butoxycarbonyl group, pentoxycarbonyl group, isopentoxycarbonyl group, neopentoxycarbonyl group, tert- pentoxycarbonyl group, 1-ethylpropoxycarbonyl group, hexyloxycarbonyl group and the like. It is preferably an alkoxycarbonyl group wherein the "alkyl moiety" is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.
  • R 1 , R 35 and R 36 particularly preferred are methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl.
  • the "-NH-alkyl” means an alkylamino group having the above-defined "alkyl group” as the alkyl moiety. Examples thereof include methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, sec- butylamino group, tert-butylamino group, pentylamino group, isopentylamino group, tert- pentylamino group, hexylamino group and the like. It is preferably an alkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.
  • R 17 , R 23 and R 30 particularly preferred are methylamino, ethylamino, propylamino and isopropylamino.
  • the "-N(-alkyl) 2 " means a dialkylamino group having the above-defined "alkyl group” as the alkyl moiety. Examples thereof include dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di(sec-butyl)amino group, di(tert-butyl)amino group, dipentylamino group, diisopentylamino group, di(tert-pentyl)amino group, dihexylamino group, N-ethyl-N- methylamino group, N-methyl-N-propylamino group, N-ethyl-N-propylamino group and the like. It is preferably a dialkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more
  • R 17 , R 23 and R 30 particularly preferred are dimethylamino, diethylamino and N- ethyl-N-methylamino.
  • alkyl group and “alkoxy group” are optionally substituted by 1 to 5 substituents each independently selected from halogen atom, -CF 3 , -OH, alkoxy group, haloalkoxy group, -N(R n )(R 12 ) (R 11 and R 12 are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO 2 , cycloalkyl group, alkenyl group, -CO-R 13 (R 13 is -OH, alkoxy group, alkyl group or -N(R 14 )(R 15 ) wherein R 14 and R 15 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group.
  • the "alkyl group" for R 17 , R 20 , R 21 and the “alkoxy group” for R 17 are optionally substituted by substituents each independently selected from -OH, -SO 2 -R 22 (R 22 is an alkyl group or -NH 2 , and R 23 is an alkyl group, -NH-alkyl, -N(-alkyl) 2 , or -NH 2 wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 ) U -N(R 24 )(R 25 )) (u is 0-3, R 24 and R 25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2 ) r CO-R 23 (t is 0-3).
  • alkyl group for R 22 and R 23 are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 ) U -N(R 24 )(R 25 )) (u is 0-3, R 24 and R 25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2 ) t -CO- R 23 (t is 0-3).
  • alkyl moieties of the "haloalkyl group” for R 6 , R 7 , R 26 , R 27 , R 28 , R 31 and R 32 , "alkylcarbonyl group” for R 12 , R 13 , R 24 , R 25 , R 35 and R 36 , "alkyloxycarbonyl group” for R 1 , R 35 and R 36 , "alkylamino group” for R 30 and “dialkylamino group” for R 30 are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R 10 )(R n ) (R 10 and R 10 are each independently a hydrogen atom or an alkyl group), an aryl group and
  • aryl group and “heteroaryl group” are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH (h is 0-3), -N(R 12 )(R 13 ) (R 12 and R 13 are each independently a hydrogen atom, an alkyl group or -CO- alkyl), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 (R 14 is -OH, an alkoxy group, an alkyl group or -N(R 15 )(R 16 ) wherein R 15 and R 16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group.
  • alkyl moieties of the "alkylamino group” for R 17 and “dialkylamino group” for R 17 are optionally substituted by substituents each independently selected from -OH, -SO 2 -R 22 (R 22 is an alkyl group or-NH 2 , and R 23 is an alkyl group, -NH-alkyl, -N(-alkyl) 2 , or -NH 2 wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 ) U -N(R 24 )(R 25 )) (u is 0-3, R 24 and R 25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2 ) t -CO-R 23 (t is 0-3).
  • alkyl moieties of the "alkylamino group” for R 23 and “dialkylamino group” for R 23 are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 ) U -N(R 24 )(R 25 )) (u is 0-3, R 24 and R 25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2 ) t -CO-R 23 (t is 0-3).
  • the "aryl group” and the “heteroaryl group” are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH (h is 0-3), -N(R 12 )(R 13 ) (R 12 and R 13 are each independently a hydrogen atom, an alkyl group or -CO-alkyl), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 (R 14 is -OH, an alkoxy group, an alkyl group or -N(R 15 )(R 16 ) wherein R 15 and R 16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group.
  • the "cycloalkyl group" for R 6 , R 7 , R 27 , R 28 , Y 1 and Y 2 and "heterocycloalkyl group” for Y and Y are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH (h is 0-3), -N(R 12 )(R 13 ) (R 12 and R 13 are each independently a hydrogen atom, an alkyl group or -CO- alkyl), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 (R 14 is -OH, an alkoxy group, an alkyl group or -N(R 15 )(R 16 ) wherein R 15 and R 16 are each independently a hydrogen atom or an alkyl group), an aryl group
  • the "cycloalkyl group" for R 1 , R 2 , R 3 , R 4 and R 5 are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO- N(R 10 )(R ⁇ ) (R 10 and R 11 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group.
  • aryl group and “heteroaryl group” are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 ) h -OH (h is 0-3), -N(R 12 )(R 13 ) (R 12 and R 13 are each independently a hydrogen atom, an alkyl group or -CO-alkyl), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14 (R 14 is -OH, an alkoxy group, an alkyl group or -N(R 15 )(R 16 ) wherein R 15 and R 16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group.
  • R 8 and R 9 in combination may form -O-alkylene-O-.
  • the "alkylene” means a divalent hydrocarbon. Examples thereof include methylene, ethylene, propylene, butylene, pentylene, hexylene and the like. It is preferably an alkylene having 1 to 6, more preferably 1 to 4, carbon atoms, particularly preferably methylene.
  • m is preferably 0; R 2 and R 3 are preferably in combination to form a Y 1 ring, which is a C 3 . 8 cycloalkane group; Ar 1 is preferably a phenyl group; R 6 and R 7 are preferably independently a halogen atom or a hydrogen atom.
  • the "pharmaceutically acceptable salt” may be any salt as long as it forms a non- toxic salt with a pyrazole compound represented by the above-mentioned formula.
  • it can be obtained by reaction with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; organic acids such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like; organic bases such as methylamine, diethylaminp, triethylamine, triethanolamine , ethylenediamine, tris(hydroxymethyl)methylamine, guanidine
  • the pyrazole compound represented by the above-mentioned formula includes various isomers.
  • the pyrazole compound represented by the above-mentioned formula includes various isomers.
  • the present invention encompasses all these isomers and mixtures thereof.
  • the present invention also encompasses prodrugs and metabolites of the pyrazole compound represented by the formula.
  • a "prodrug” is a derivative of the compound of the present invention, which has a chemically or metabohcally decomposable group, which, after being administered to a living organism, is restored to its original compound form and exhibits its intrinsic efficacy, and which includes complexes and salts free of a covalent bond.
  • ester derivatives known as prodrugs in the field of pharmaceutical agents can be used.
  • the compound of the present invention is used as a pharmaceutical preparation, it is generally admixed with a pharmaceutically acceptable carrier, excipient, diluent, extender, disintegrant, stabilizer, preservative, buffer, emulsifier, fragrance, coloring agent, sweetening agent, thickening agent, co ⁇ igent, dissolution aids and other additives known per se, such as water, vegetable oil, alcohols such as ethanol, benzyl alcohol and the like, polyethylene glycol, glycerol triacetate, gelatin, lactose, carbohydrates such as starch and the like, magnesium stearate, talc, lanolin, vaseline and the like, and produced in the form of tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche , aerosol, elixir, suspension, emulsion, syrup and the like by a conventional method for systemic or local, oral or parenteral administration.
  • a pharmaceutically acceptable carrier such as water, vegetable
  • the dose of the compound of the present invention varies depending on the age, body weight, symptom, disease to be treated, administration method and the like, it is generally 1 mg to 1000 mg for an adult per administration, which is given once to several times a day.
  • the compound of the present invention can be administered to a mammal (human, mouse, rat, rabbit, dog, cat, bovine, pig, monkey etc.) as an HSDl inhibitor, a prophylactic or therapeutic drug of diabetes, a prophylactic or therapeutic drug of diabetic complication (retinopathy, nephropathy, neuropathy, cardiac infarction and cerebral infarction based on arteriosclerosis etc.), a prophylactic or therapeutic drug of hyperlipemia, a prophylactic or therapeutic drug of obesity, neurodegenerative disease and the like, or a prophylactic or therapeutic drug of diseases mediated by HSD 1.
  • a mammal human, mouse, rat, rabbit, dog, cat, bovine, pig, monkey etc.
  • a prophylactic or therapeutic drug of diabetes a prophylactic or therapeutic drug of diabetic complication (retinopathy, nephropathy, neuropathy, cardiac infarction and cerebral infarction based on arteriosclerosis etc.)
  • the compound of the present invention can be administered to a mammal concurrently with other therapeutic drug of diabetes or obesity with the aim of the prophylaxis or treatment of diabetes.
  • the "therapeutic drug of diabetes” encompasses therapeutic drugs of diabetic complications.
  • the compound of the present invention can be administered in combination with other therapeutic drugs of diabetes or obesity to a mammal for the prophylaxis or treatment of obesity.
  • the compound of the present invention may be administered simultaneously with other therapeutic drugs of diabetes or other therapeutic drugs of obesity (hereinafter to be referred to as a combined pharmaceutical agent) or may be administered at time intervals.
  • a pharmaceutical composition containing the compound of the present invention and a combined pharmaceutical agent can be administered.
  • a pharmaceutical composition containing the compound of the present invention and a pharmaceutical composition containing a combined pharmaceutical agent may be administered separately.
  • the administration routes of respective pharmaceutical compositions may be the same or different.
  • the compound of the present invention may be administered at a dose of 1 mg to 1000 mg per administration, which is given once to several times a day.
  • the compound may be administered at a smaller dose.
  • the combined pharmaceutical agent can be administered at a dose generally employed for the prophylaxis or treatment of diabetes or obesity or at a smaller dose than that.
  • insulin preparation As other therapeutic drug of diabetes to be used for the combined administration, insulin preparation, sulfonylurea, insulin secretagogue, sulfonamide, biguanide, - glucosidase inhibitor, PTP1B inhibitor, insulin sensitizer and the like can be mentioned.
  • insulin for example, insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose, pioglitazone hydrochloride and the like can be used for combined administration with the compound of the present invention.
  • mazindol As other therapeutic drug of obesity to be used for the combined administration, for example, mazindol can be mentioned.
  • a pyrazole compound is produced, and the method includes any of the following steps.
  • Diketone (1) synthesized by a known method and hydrazine hydrate (2) are reacted in a solvent to give pyrazole (3).
  • a solvent methanol, ethanol, n-propanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran (THF), acetic acid, 1,4-dioxane, N,N- dimethylformamide, dimethyl sulfoxide, dichloromethane, 1,2-dichloroethane, chloroform, benzene, chlorobenzene, o-dichlorobenzene, toluene, xylene, pyridine, acetic acid, or a mixed solvent thereof can be mentioned.
  • the reaction temperature is preferably 20°C - 250°C.
  • Example 1-1 Production of 3-(2,4-dichlorophenyl)-4-methyl-5-((l- ⁇ henylcyclopropane)-l- yl)- pyrazole [0123] l-(2,4-dichlorophenyl)-2-methyl-3-(l-phenylcyclopropane)-propane-l,3-dione (347 mg) were suspended in acetic acid (4 mL) and ethanol (2 mL), hydrazine hydrate (100 mg) was added and the mixture was heated for 3 hours at 80 °C.
  • reaction solution was concentrated and extracted with ethyl acetate.
  • the ethyl acetate layer was washed successively with saturated brine, dried over anhydrous sodium sulfate, and concentrated to dryness.
  • Examples 1-2 to 1-16 [0124] In the same manner as in Example 1-1, and using other conventional methods as necessary, a pyrazole compound was produced. The structural formula and property values of each Example compound are shown in the following Table.
  • HSDl hydroxysteroid dehydrogenase 1 activity inhibitory action
  • SPA sintillation proximity assay
  • a reagent was added to a 96 well plate (96 well Opti-platesTM-96 (Packard)) to the following final concentration and a volume of 100 ⁇ l was reacted at room temperature for 90 min.
  • reaction solution used was 0.1 ⁇ g/mL recombinant HSD 1 , 500 ⁇ M NADPH, 16 nM 3 H cortisone (Amersham Biosciences, 1.78 Tbq/mol) dissolved in 0.1% BSA (Sigma)-containing PBS and the test drug was 2 ⁇ l of a compound solution (dissolved in DMSO).
  • the reaction was stopped by adding PBS (40 ⁇ l, containing 0.1% BSA (Sigma)) containing 0.08 ⁇ g of anti-cortisol mouse monoclonal antibody (East Coast Biologies), 365 ⁇ g SPA PNT mouse antibody-binding beads (Amersham Biosciences) and 175 ⁇ M carbenoxolone (Sigma) to the reaction solution. After the completion of the reaction, the plate was incubated overnight at room temperature and the radioactivity was measured by Topcount (Packard).
  • Examples 2-1 to 2-45 [0127] In the same manner as in Example 1-1, and using other conventional methods as necessary, the pyrazole compounds shown in the following Table can be also produced.
  • the pyrazole compound of the present invention has superior HSDl inhibitory activity and is useful as an HSDl inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.

Description

PYRAZOLE COMPOU1NDS AND USES RELATED THERETO
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60/556,013, filed March 23, 2004, the content of which is incorporated herein by reference.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] NOT APPLICABLE
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK.
[0003] NOT APPLICABLE BACKGROUND OF THE INVENTION
[0004] The present invention relates to pyrazole compounds having HSDl inhibitory activity. 11-Beta-hydroxysteroid dehydrogenase 1 (hereinafter, "110-HSD1" or "HSDl") catalyzes the interconversion of glucocorticoids (hereinafter, "GC") between inert 11-keto forms (e.g. cortisone, 11-dehydrocorticosterone) and active 11/3-hydroxy forms (e.g. cortisol, corticosterone, respectively). The enzyme, in vivo, prefers the reductase direction from 11- keto to 11/5 -hydroxy, in other words, the production of active GC.
[0005] 11/3-HSD1 is ubiquitously expressed, most notably in liver, lung, adipose tissue, vasculature, ovary and the central nervous system.
[0006] Recently, experimental results have suggested that the active form of GC produced through HSDl as well as the enzyme itself is involved in several biological actions and diseases.
[0007] For example, the active GC is known to stimulate gluconeogenic enzymes and have effects at least in part in inducing hyperglycemia. In this situation, HSDl can be a second source of GC production in addition to the adrenal glands. [0008] As another example, continuous excess of the active GC in peripheral tissues, as observed in Cushing's syndrome, leads to insulin resistance, where HSDl is considered to have an important role.
[0009] Also, in adipose tissue, active GC has been demonstrated to enhance the differentiation of preadipocytes into adipocytes. Mature adipocytes express HSDl activity, which causes an increase in local concentration of the active form and further expansion of adipose tissue. Such an action of HSDl should be critical in pathogenesis of obesity.
[0010] In addition, a local immunosuppressive effect of HSDl in placental deciduas, and a relationship between the expression of the enzyme in adrenal cortex and the induction of adrenaline synthesis, have been suggested.
[0011] (The above are referred to in: Quinkler M, Oelkers W & Diederich S (2001) European Journal of Endocrinology Vol. 144, Pages 87-97; and Seckl JR & Walker BR (2001) Endocrinology Vol. 142, Pages 1371-1376.)
[0012] According to the above suggestions, it is expected that drugs having inhibitory effects against HSDl would be useful for treating or preventing diabetes mellitus, obesity, metabolic syndrome in connection with any of such diseases, or any other diseases which occur by reason of the actions of HSDl.
[0013] Diabetes mellitus, the main feature of which disease is chronic hyperglycemia, introduces various metabolic abnormalities and shows symptoms of thirst, polydipsia, polyuria, and so on based on high glucose concentration. A continuing hyperglycemic state can also lead to diabetic complications such as retinopathy, nephropathy, neuropathy, and myocardial and/or cerebral infarction by reason of arteriosclerosis.
[0014] In treating diabetes, moderate suppression of hyperglycemia is critical in order that onset and progress of the complications would be repressed. For these purposes, dietetics, ergotherapy and pharmacotherapy are utilized in combination on a suitable basis and, amongst the pharmacotherapy, many approaches different in mechanisms of action have been attempted. In spite of those various existing methods, sufficient therapeutic effect has not ever been achieved.
[0015] Obesity is defined as a state of fatness coinciding with any disease that would be improved or not be progressed in case of weight decrease (e.g. diabetes, hyperlipidemia, hypertension) or with an excessive amount of fat in viscera. It is considered that, if such a state should continue, at least two of diabetes, hyperlipidemia, hypertension and related disorders would concur, followed by the onset of myocardial and/or cerebral infarction by reason of arteriosclerosis.
[0016] Major therapeutic methods in treating obesity are dietetics and ergotherapy, and pharmacotherapy is undertaken only if necessary, for example, because of difficulty in the first two alternatives. However, the existing drugs have several problems in adverse effects and usages, since most of them suppress feeding mainly via central action.
[0017] In consequence, development of any drug to treat diabetes and/or obesity with a novel mechanism of action has so far been required. Under these circumstances, it is expected that drugs having inhibitory effects against HSD 1 would be useful as another alternative with separate mechanistic approach to treat diabetes mellitus, as well as a novel "adipose tissue-acting" class among other drugs against obesity.
[0018] As drugs in development to treat diabetes and/or obesity through inhibition of HSDl, for example, WO 03/104207 and WO 03/104208 disclose triazole compounds of the following general formula:
Figure imgf000004_0001
wherein:
[0019] A and B are taken separately or together;
[0020] when taken separately, A is halo, unsubstituted or substituted Cι-6alkyl, unsubstituted or substituted OCι-6alkyl or unsubstituted or substituted phenyl and B is -H, halo, unsubstituted or substituted Ci-βalkyl, unsubstituted or substituted OCι-6alkyl, unsubstituted or substituted -S -βalkyl, unsubstituted or substituted C2-6alkenyl, unsubstituted or substituted phenyl or unsubstituted or substituted naphthyl; and
[0021] when taken together, unsubstituted or substituted Cι-4alkylene or unsubstituted or substituted C2.5alkanediyl;
[0022] each R1 is -H, -OH, halo, unsubstituted or substituted .ioalkyl, unsubstituted or substituted Cι-6alkoxy or unsubstituted or substituted C6.10aryl, or two R1 taken together are a fused C5.6alkyl (either unsubstituted or substituted) or unsubstituted or substituted aryl ring; [0023] R2 and R3 are taken separately or together;
[0024] when taken together, (a) a C3-8 alkanediyl forming a fused 5-10 membered non- aromatic ring (optionally interrupted with 1-2 double bonds, either unsubstituted or substituted) or (b) a fused 6-10 membered aromatic monocyclic (either unsubstituted or substituted) or bicyclic group (either unsubstituted or substituted);
[0025] when taken separately, R2 is C1.-.4 alkyl (either unsubstituted or substituted), unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, either unsubstituted or substituted C2-_0 alkenyl, -CH2CO2H, -CH2CO2Cι-6alkyl, -CH2C(O)NHRa, -NH2, -NHRa or N(Ra) and R3 is unsubstituted or substituted Ci^a-kyl, unsubstituted or substituted C2- 10alkenyl, unsubstituted or substituted SCι-6alkyl, unsubstituted or substituted Cβ-ioaryl, unsubstituted or substituted heterocyclyl or unsubstituted or substituted heteroaryl;
[0026] Ra is unsubstituted or substituted C_-3 alkyl, unsubstituted or substituted OCι-3 alkyl, unsubstituted or substituted C6-ι0 ArCι-6alkylene or unsubstituted or substituted phenyl;
[0027] However, the description provided in the noted applications does not disclose or suggest any of the compounds having the structure of the present invention.
[0028] The compounds of the present invention improve physicochemical (stability, etc.) and biological (activity to inhibit HSDl, specificity, bioavailability, metabolism, etc.) profiles, as a result of the selection of structural characteristics as disclosed herein. BRIEF SUMMARY OF THE INVENTION
[0029] According to the present invention, it has been found that pyrazole compounds represented by the following formula have superior HSDl inhibitory activity, and are useful as HSDl inhibitors or therapeutic drugs for the treatment of diabetes or obesity.
[0030] The present invention provides the following:
[0031] In one aspect, the present invention provides pyrazole compounds represented by the following formula:
Figure imgf000005_0001
wherein
[0032] R1 is a hydrogen atom, -CO-O-alkyl, -COOH, an alkyl group, an alkoxy group or a cycloalkyl group, wherein the alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R10)(Rn), -N(R10)-CO-Rπ, an aryl group and a heteroaryl group, wherein R10 and R11 are each independently a hydrogen atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group, wherein h is 0-3, R12 and R13 are each independently a hydrogen atom, an alkyl group or -CO-alkyl, and R14 is -OH, an alkoxy group, an alkyl group or -N(R15)(R16), wherein R15 and R16 are each independently a hydrogen atom or an alkyl group;
[0033] R2, R3, R4 and R5 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a cycloalkyl group or R2 and R3, and/or R4 and R5 in combination with the carbon atoms to which they are attached form a ring represented by
Figure imgf000006_0001
wherein the Y1 ring is a cycloalkane or a heterocycloalkane group, the wavy lines indicate the point of attachment to the remainder of the molecule and wherein the cycloalkane group and the heterocycloalkane group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH )h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group (h, R12, R13 and R14 are as defined above),
[0034] wherein the alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R10)(Rn), an aryl group and a heteroaryl group [0035] wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group (R10, R11, h, R12, R13 and R14 are as defined above);
[0036] the subscript n is an integer of from 0 to 3;
[0037] Ar1 is an aryl group or a heteroaryl group;
[0038] R6 and R7 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH2)j-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group or heteroaryl group, wherein j is 0-3, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group (R12, R13, R14 and h are as defined above);
[0039] the subscript m is an integer of from 0 to 3 ;
[0040] R8 and R9 are each independently a hydrogen atom, a halogen atom, -OH, -NO2, -CN, an alkyl group, an alkoxy group, -CO-R17, -SO2-R17, -CO-N(R18)(R19), -N(R20)(R21) or in combination form -O-alkylene-O-, wherein the alkyl group and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R10)(Rπ), -N(R10)-CO-Rπ, an aryl group and a heteroaryl group, wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group (R10, R11, h, R12, R13 and R15 are as defined above),
[0041] R17 is -OH, an alkoxy group, an alkyl group, -NH2, -NH-alkyl or -N(-alkyl)2, wherein the alkoxy group and alkyl groups are optionally substituted by substituents each independently selected from -OH, -SO2-R22 and -(CH2)t-CO-R23, wherein t is 0-3, R22 is an alkyl group or -NH2, and R23 is an alkyl group, -NH-alkyl, -N(-alkyl)2, or -NH2, wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH2)U-N(R24)(R25), wherein u is 0-3, and R24 and R25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl,
[0042] R18 and R19 are each independently a hydrogen atom, an alkyl group or -(CH2)P-R26, wherein p is 0-3 and R26 is -OH, a haloalkyl group, an alkoxy group, -CO-NH2 or -N(R 4)(R25), wherein R24 and R25 are as defined above;
[0043] R20 and R21 are each independently a hydrogen atom, an alkyl group -CO-R23 or in combination with the nitrogen atom to which each is attached, form
Figure imgf000008_0001
wherein the alkyl group is optionally substituted by substituents each independently selected from -OH, -SO2-R22 and -(CH2)rCO-R23 (wherein R22 and R23 are as defined above), X1 is -CO-, -CH2- or -CH2-CH2-, X2 is -O-, -(CH2)q- or -N(R29)- or a spirocyclic ring represented by
Figure imgf000008_0002
wherein q is 0-2, R29 is a hydrogen atom, -CO-R30, -SO2-R30 or -(CH2)r-Ar3, wherein R30 is an alkyl group, an alkoxy group, -NH-alkyl or -N(-alkyl)2, r is 0-3, and Ar3 is an aryl group or heteroaryl group, wherein the aryl group and heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group (h, R12, R13 and R14 are as defined above), and the spirocyclic Y πng is a spiro-cycloalkyl or spiro-heterocycloalkyl ring, and R27 and R28 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH )h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group or a heteroaryl group (h, R12, R13 and R14 are as defined above);
[0044] Ar2 is an aryl group, a heteroaryl group or a ring having the formula
Figure imgf000009_0001
wherein N1 is CH or Ν, X3 is -(CH2)v-5 wherein v is 0-2, and W1 is -C(R31)(R32)-, -CO- or -Ν(R33)-, wherein R31 and R32 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, -(CH2)w-OH, -CO-R34, -L!-Ar4 or -N(R35)(R36), wherein w is 0-3, R34 is -OH, an alkoxy group, an alkyl group or -N(R37)(R38), wherein R37 and R38 are each independently a hydrogen atom, an alkyl group, -(CH2)x-OH or an alkoxy group, wherein x is 0-3, L1 is -(CH2)y-, -O- or -CO-, wherein y is 0-3, Ar4 is an aryl group or a heteroaryl group, wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group (h, R12, R13 and R14 are as defined above), and R35 and R36 are each independently a hydrogen atom, an alkyl group, -CO-alkyl, -CO-O-alkyl or L!-Ar4 (L1 and Ar4 are as defined above), and R33 is a hydrogen atom, -CO-R28, -SO2-R28 or -(CH2)k-Ar3, wherein k is 0-3 (R28 and Ar3 are as defined above); and
[0045] the pyrazole ring (labeled A) provided as
is selected from
Figure imgf000009_0002
[0046] or a prodrug thereof or a pharmaceutically acceptable salt thereof.
[0047] In the above compounds of the invention, any variable used to define another variable is meant to have its most complete meaning as provided above, unless otherwise stated. Additionally, when a letter subscript is provided with a range (e.g., x and y being 0 to 3), the lower limit (0) is meant to indicate the presence of a bond. [0048] In some embodiments, the pyrazole compound has the formula above, wherein the subscript m is 0, a prodrug thereof or a pharmaceutically acceptable salt thereof.
[0049] In other embodiments, the pyrazole compound has the formula above, wherein the subscript m is 0, and where R and R are in combination with the carbon atom to which they are attached to form
Figure imgf000010_0001
wherein the Y1 ring is a C3.8 cycloalkane group, and the compounds further include a prodrug thereof or a pharmaceutically acceptable salt thereof. Within this group of embodiments, preferably Ar1 is an phenyl group. Still further preferred are those embodiments in which R6 and R7 are each independently a halogen atom or a hydrogen atom.
[0050] In another aspect, the present invention provides a pharmaceutical composition comprising one or more of the pyrazole compounds described above, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0051] In yet another aspect, the present invention provides a HSDl (11/3-hydroxysteroid dehydrogenase 1) inhibitor comprising a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
[0052] In a related aspect, the present invention provides a therapeutic or prophylactic drug for diabetes, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
[0053] In another aspect, the present invention provides a therapeutic or prophylactic drug for obesity, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
[0054] In yet another aspect, the present invention provides a therapeutic or prophylactic drug for metabolic syndrome, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
[0055] In still another aspect, the present invention provides a method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of a pyrazole compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
[0056] In another aspect, the present invention provides a method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of a pyrazole compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
[0057] In yet another aspect, the present invention provides a method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of a pyrazole compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
[0058] In still another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above, in combination with a different therapeutic drug for the treatment of diabetes. Preferably, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an c--glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer. In other preferred embodiments, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
[0059] In another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for obesity, which is used in combination with a different therapeutic drug for the treatment of diabetes. Preferably, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an α-glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer. In other preferred embodiments, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride. [0060] In yet another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for metabolic syndrome, which is used in combination with a different therapeutic drug for the treatment of diabetes. Preferably, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an α-glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer. hi other preferred embodiments, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
[0061] In still another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for diabetes, which is used in combination with a different therapeutic drug for the treatment of obesity. Preferably, the different therapeutic drug for obesity is Mazindol.
[0062] In another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for obesity, which is used in combination with a different therapeutic drug for the treatment of obesity. Preferably, the different therapeutic drug for obesity is Mazindol.
[0063] In yet another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for metabolic syndrome, which is used in combination with a different therapeutic drug for the treatment of obesity. Preferably, the different therapeutic drug for obesity is Mazindol. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Not applicable.
DETAILED DESCRIPTION OF THE INVENTION
[0065] Compounds of the present invention have been described above. More specifically, respective substituents and moieties used in the present specification are defined in the following. [0066] The "alkyl group" means a straight chain or branched chain alkyl group. Examples thereof include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group, 1-ethylpropyl group, hexyl group and the like. It is preferably a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.
[0067] For R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R27, R28, R30, R31, R32, R34, R35, R36, R37 and R38, preferred are methyl, ethyl, propyl, isopropyl, butyl and isobutyl, and particularly preferred are methyl and isopropyl.
[0068] The "cycloalkyl group" means a saturated cyclic alkyl group. Examples thereof include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group and the like. It is preferably a cycloalkyl group having 3 to 8, more preferably 3 to 6, carbon atoms.
[0069] For R1, R2, R3, R4, R5, R6, R7, R27, R28, Y1 and Y2, preferred are cyclopropyl, cyclobutyl and cyclopentyl, and particularly preferred is cyclopropyl. In the case of Y1 and Y2, the rings are attached in a spirocyclic manner to the remainder of the molecule.
[0070] The "heterocycloalkyl group" means a saturated 5- to 7-membered heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Examples thereof include tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, pyrazolidinyl group, imidazolidinyl group, oxazolidinyl group, thiazolidinyl group, tetrahydropyranyl group, dioxolanyl group, dioxanyl group, piperidinyl group, piperazinyl group, morpholinyl group and the like.
[0071] For Y and Y , preferred is piperidinyl, which in the case of the Y ring is attached in a spirocyclic manner to the remainder of the molecule.
[0072] The "alkenyl group" means a straight chain or branched chain alkenyl group. Examples thereof include vinyl group, 1-propenyl group, allyl group, l-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 2-pentenyl group, 1-hexenyl group, 2-hexenyl group and the like. It is preferably a straight chain or branched chain alkenyl group having 2 to 6, more preferably 2 to 4, carbon atoms.
[0073] For R6, R7, R27 and R28, preferred is vinyl. [0074] The "aryl group" means an aromatic hydrocarbon group. Examples thereof include phenyl group, naphthyl group, anthryl group and the like. It is preferably a phenyl group or naphthyl group.
[0075] For R6, R7, R27, R28, Ar1, Ar2, Ar3 and Ar4, preferred are phenyl and naphthyl, and particularly preferred is phenyl.
[0076] The "heteroaryl group" means a monocyclic or fused 5- to 14-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Examples thereof include furyl group, thienyl group, pyrrolyl group, oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzoxazolyl group, indolizinyl group, quinolyl group, isoquinolyl group, quinazolinyl group, cinnolinyl group, quinoxalinyl group, phthalazinyl group, acridinyl group, phenazinyl group, naphthyridinyl group and the like. It is preferably a monocyclic or fused 5- to 10-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which includes furyl group, thienyl group, pyrrolyl group, oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzooxazolyl group and the like.
[0077] For R6, R7, Ar1, preferred are thienyl, pyrrolyl and pyridyl.
[0078] For R27, R28, Ar2, preferred are thienyl, pyrrolyl, oxazolyl, isooxazolyl, thiazolyl, imidazolyl, pyrazolyl and pyridyl, and particularly preferred are thienyl and pyridyl.
[0079] For Ar3 and Ar4, preferred is pyridyl.
[0080] The "halogen atom" means fluorine atom, chlorine atom, bromine atom or iodine atom. It is preferably fluorine atom or chlorine atom.
[0081] For R6 and R7, preferred is fluorine atom or chlorine atom. In this case, Ar1 is particularly preferably phenyl, where only the 4-position of the phenyl is substituted by fluorine atom or chlorine atom. [0082] For R8 and R9, preferred is chlorine atom. In this case, Ar2 is particularly preferably phenyl, where at least the 2-position of the phenyl is substituted by chlorine atom.
[0083] For R27 and R28, preferred are fluorine atom or chlorine atom.
[0084] The "haloalkyl group" means a haloalkyl group wherein the above-defined "alkyl group" is substituted by the above-defined "halogen atom". Examples thereof include fluoromethyl group, difluoromethyl group, trifluoromethyl group, bromomethyl group, chloromethyl group, 1,2-dichloroethyl group, 2,2-dichloroethyl group, 2,2,2-trifluoroethyl group and the like. It is preferably a straight chain or branched chain haloalkyl group having 1 to 6, more preferably 1 to 4, carbon atoms, particularly preferably a trifluoromethyl group.
[0085] For R6, R7, R26, R27, R28, R31 and R32, preferred are fluoromethyl group, difluoromethyl group or trifluoromethyl group.
[0086] The "alkoxy group" means a straight chain or branched chain alkoxy group. Examples thereof include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, tert-butoxy group, pentyloxy group, hexyloxy group and the like. It is preferably a straight chain or branched chain alkoxy group having 1 to 6, more preferably 1 to 4, carbon atoms.
[0087] For R1, R2, R3, R4, R5, R6, R7, R8, R9, R14, R17, R26, R27, R28, R30, R31, R32, R34, R37 and R38, preferred are methoxy, ethoxy and isopropoxy.
[0088] The "-CO-alkyl" means an alkylcarbonyl group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, pentanoyl group, hexanoyl group and the like. It is preferably an alkylcarbonyl group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms. [0089] For R12, R13, R24, R25, R35 and R36, particularly preferred are acetyl, propionyl, butyryl and isobutyryl.
[0090] The "-CO-O-alkyl" means an alkoxycarbonyl group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, sec-butoxycarbonyl group, tert-butoxycarbonyl group, pentoxycarbonyl group, isopentoxycarbonyl group, neopentoxycarbonyl group, tert- pentoxycarbonyl group, 1-ethylpropoxycarbonyl group, hexyloxycarbonyl group and the like. It is preferably an alkoxycarbonyl group wherein the "alkyl moiety" is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.
[0091] For R1, R35 and R36, particularly preferred are methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl.
[0092] The "-NH-alkyl" means an alkylamino group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, sec- butylamino group, tert-butylamino group, pentylamino group, isopentylamino group, tert- pentylamino group, hexylamino group and the like. It is preferably an alkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.
[0093] For R17, R23 and R30, particularly preferred are methylamino, ethylamino, propylamino and isopropylamino.
[0094] The "-N(-alkyl)2" means a dialkylamino group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di(sec-butyl)amino group, di(tert-butyl)amino group, dipentylamino group, diisopentylamino group, di(tert-pentyl)amino group, dihexylamino group, N-ethyl-N- methylamino group, N-methyl-N-propylamino group, N-ethyl-N-propylamino group and the like. It is preferably a dialkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.
[0095] For R17, R23 and R30, particularly preferred are dimethylamino, diethylamino and N- ethyl-N-methylamino.
[0096] The "alkyl group" and "alkoxy group" are optionally substituted by 1 to 5 substituents each independently selected from halogen atom, -CF3, -OH, alkoxy group, haloalkoxy group, -N(Rn)(R12) (R11 and R12 are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO2, cycloalkyl group, alkenyl group, -CO-R13 (R13 is -OH, alkoxy group, alkyl group or -N(R14)(R15) wherein R14 and R15 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. Here, the substituent "aryl group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from halogen atom, haloalkyl group, alkyl group, -(CH2)n-OH (n=0 - 3), -N(Rn)(R12) (R11 and R12 are independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO2, alkoxy group, cycloalkyl group, alkenyl group, -CO-R13 (R13 is -OH, alkoxy group, alkyl group or -N(R14)(R15) wherein R14 and R15 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group.
[0097] The "alkyl group" for R17, R20, R21 and the "alkoxy group" for R17 are optionally substituted by substituents each independently selected from -OH, -SO2-R22 (R22 is an alkyl group or -NH2, and R23 is an alkyl group, -NH-alkyl, -N(-alkyl)2, or -NH2 wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH2)U-N(R24)(R25)) (u is 0-3, R24 and R25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH2)rCO-R23 (t is 0-3).
[0098] The "alkyl group" for R22 and R23 are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH2)U-N(R24)(R25)) (u is 0-3, R24 and R25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH2)t-CO- R23 (t is 0-3).
[0099] The "alkyl" moieties of the "haloalkyl group" for R6, R7, R26, R27, R28, R31 and R32, "alkylcarbonyl group" for R12, R13, R24, R25, R35 and R36, "alkyloxycarbonyl group" for R1, R35 and R36, "alkylamino group" for R30 and "dialkylamino group" for R30 are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R10)(Rn) (R10 and R10 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. Here, the substituent "aryl group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH (h is 0-3), -N(R12)(R13) (R12 and R13 are each independently a hydrogen atom, an alkyl group or -CO- alkyl), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14 (R14 is -OH, an alkoxy group, an alkyl group or -N(R15)(R16) wherein R15 and R16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group.
[0100] The "alkyl" moieties of the "alkylamino group" for R17 and "dialkylamino group" for R17 are optionally substituted by substituents each independently selected from -OH, -SO2-R22 (R22 is an alkyl group or-NH2, and R23 is an alkyl group, -NH-alkyl, -N(-alkyl)2, or -NH2 wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH2)U-N(R24)(R25)) (u is 0-3, R24 and R25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH2)t-CO-R23 (t is 0-3).
[0101] The "alkyl" moieties of the "alkylamino group" for R23 and "dialkylamino group" for R23 are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH2)U-N(R24)(R25)) (u is 0-3, R24 and R25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH2)t-CO-R23 (t is 0-3).
[0102] The "aryl group" and the "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH (h is 0-3), -N(R12)(R13) (R12 and R13 are each independently a hydrogen atom, an alkyl group or -CO-alkyl), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14 (R14 is -OH, an alkoxy group, an alkyl group or -N(R15)(R16) wherein R15 and R16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group.
[0103] The "cycloalkyl group" for R6, R7, R27, R28, Y1 and Y2 and "heterocycloalkyl group" for Y and Y are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH (h is 0-3), -N(R12)(R13) (R12 and R13 are each independently a hydrogen atom, an alkyl group or -CO- alkyl), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14 (R14 is -OH, an alkoxy group, an alkyl group or -N(R15)(R16) wherein R15 and R16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group.
[0104] The "cycloalkyl group" for R1, R2, R3, R4 and R5 are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO- N(R10)(Rπ) (R10 and R11 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. Here, the substiruent "aryl group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH (h is 0-3), -N(R12)(R13) (R12 and R13 are each independently a hydrogen atom, an alkyl group or -CO-alkyl), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14 (R14 is -OH, an alkoxy group, an alkyl group or -N(R15)(R16) wherein R15 and R16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. [0105] The above-mentioned substituents "alkyl group", "cycloalkyl group", "heterocycloalkyl group", "alkenyl group", "aryl group", "heteroaryl group", "halogen atom", "haloalkyl group", "alkoxy group", "haloalkoxy group" are as defined above.
[0106] R8 and R9 in combination may form -O-alkylene-O-. Here, the "alkylene" means a divalent hydrocarbon. Examples thereof include methylene, ethylene, propylene, butylene, pentylene, hexylene and the like. It is preferably an alkylene having 1 to 6, more preferably 1 to 4, carbon atoms, particularly preferably methylene.
[0107] In the above-mentioned formulae, m is preferably 0; R2 and R3 are preferably in combination to form a Y1 ring, which is a C3.8 cycloalkane group; Ar1 is preferably a phenyl group; R6 and R7 are preferably independently a halogen atom or a hydrogen atom.
[0108] The "pharmaceutically acceptable salt" may be any salt as long as it forms a non- toxic salt with a pyrazole compound represented by the above-mentioned formula. For example, it can be obtained by reaction with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; organic acids such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like; organic bases such as methylamine, diethylaminp, triethylamine, triethanolamine , ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, cinchonine, N- methyl-D-glucamine and the like; or amino acids such as lysin, histidine, arginine, alanine and the like. In the present invention, a water-containing form, a hydrate and a solvate of each compound are also encompassed therein.
[0109] In addition, the pyrazole compound represented by the above-mentioned formula includes various isomers. For example,
Figure imgf000019_0001
forms are present as tautomers, and when an asymmetric carbon atom is present, enantiomers and diastereomers are present as stereoisomers based thereon. In some cases, geometric isomers may be present. Accordingly, the present invention encompasses all these isomers and mixtures thereof.
[0110] The present invention also encompasses prodrugs and metabolites of the pyrazole compound represented by the formula. A "prodrug" is a derivative of the compound of the present invention, which has a chemically or metabohcally decomposable group, which, after being administered to a living organism, is restored to its original compound form and exhibits its intrinsic efficacy, and which includes complexes and salts free of a covalent bond. For example, ester derivatives known as prodrugs in the field of pharmaceutical agents can be used. [0111] When the compound of the present invention is used as a pharmaceutical preparation, it is generally admixed with a pharmaceutically acceptable carrier, excipient, diluent, extender, disintegrant, stabilizer, preservative, buffer, emulsifier, fragrance, coloring agent, sweetening agent, thickening agent, coπigent, dissolution aids and other additives known per se, such as water, vegetable oil, alcohols such as ethanol, benzyl alcohol and the like, polyethylene glycol, glycerol triacetate, gelatin, lactose, carbohydrates such as starch and the like, magnesium stearate, talc, lanolin, vaseline and the like, and produced in the form of tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche , aerosol, elixir, suspension, emulsion, syrup and the like by a conventional method for systemic or local, oral or parenteral administration.
[0112] While the dose of the compound of the present invention varies depending on the age, body weight, symptom, disease to be treated, administration method and the like, it is generally 1 mg to 1000 mg for an adult per administration, which is given once to several times a day.
[0113] The compound of the present invention can be administered to a mammal (human, mouse, rat, rabbit, dog, cat, bovine, pig, monkey etc.) as an HSDl inhibitor, a prophylactic or therapeutic drug of diabetes, a prophylactic or therapeutic drug of diabetic complication (retinopathy, nephropathy, neuropathy, cardiac infarction and cerebral infarction based on arteriosclerosis etc.), a prophylactic or therapeutic drug of hyperlipemia, a prophylactic or therapeutic drug of obesity, neurodegenerative disease and the like, or a prophylactic or therapeutic drug of diseases mediated by HSD 1.
[0114] The compound of the present invention can be administered to a mammal concurrently with other therapeutic drug of diabetes or obesity with the aim of the prophylaxis or treatment of diabetes. In the present invention, the "therapeutic drug of diabetes" encompasses therapeutic drugs of diabetic complications. Furthermore, the compound of the present invention can be administered in combination with other therapeutic drugs of diabetes or obesity to a mammal for the prophylaxis or treatment of obesity.
[0115] In the case of a combined administration, the compound of the present invention may be administered simultaneously with other therapeutic drugs of diabetes or other therapeutic drugs of obesity (hereinafter to be referred to as a combined pharmaceutical agent) or may be administered at time intervals. In the case of a combined administration, a pharmaceutical composition containing the compound of the present invention and a combined pharmaceutical agent can be administered. Alternatively, a pharmaceutical composition containing the compound of the present invention and a pharmaceutical composition containing a combined pharmaceutical agent may be administered separately. The administration routes of respective pharmaceutical compositions may be the same or different.
[0116] In the case of a combined administration, the compound of the present invention may be administered at a dose of 1 mg to 1000 mg per administration, which is given once to several times a day. In addition, the compound may be administered at a smaller dose. The combined pharmaceutical agent can be administered at a dose generally employed for the prophylaxis or treatment of diabetes or obesity or at a smaller dose than that.
[0117] As other therapeutic drug of diabetes to be used for the combined administration, insulin preparation, sulfonylurea, insulin secretagogue, sulfonamide, biguanide, - glucosidase inhibitor, PTP1B inhibitor, insulin sensitizer and the like can be mentioned. For example, insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose, pioglitazone hydrochloride and the like can be used for combined administration with the compound of the present invention.
[0118] As other therapeutic drug of obesity to be used for the combined administration, for example, mazindol can be mentioned.
[0119] One example of the production method of the pyrazole compound of the present invention is described in the following, which does not limit the production method of the compound of the present invention. Even in the absence of description in the production method, efficient production can be afforded by introducing, where necessary, a protecting group into a functional group followed by deprotection in a subsequent step, exchanging the order of respective production methods and steps, and the like. The post-reaction treatment can be applied by a typical method by selecting or combining conventional methods as necessary, such as isolation and purification, crystallization, recrystallization, silica gel chromatography, preparative HPLC and the like.
Production Method 1
[0120] In this production method, a pyrazole compound is produced, and the method includes any of the following steps.
Figure imgf000022_0001
(1) (2)
Figure imgf000022_0002
(3) wherein each symbol is as defined above.
[0121] Diketone (1) synthesized by a known method and hydrazine hydrate (2) are reacted in a solvent to give pyrazole (3). As the solvent, methanol, ethanol, n-propanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran (THF), acetic acid, 1,4-dioxane, N,N- dimethylformamide, dimethyl sulfoxide, dichloromethane, 1,2-dichloroethane, chloroform, benzene, chlorobenzene, o-dichlorobenzene, toluene, xylene, pyridine, acetic acid, or a mixed solvent thereof can be mentioned. The reaction temperature is preferably 20°C - 250°C.
Examples
[0122] The pyrazole compound represented by the formula of the present invention and the production method thereof are explained in detail in the following by referring to Examples, which are not to be construed as limitative. Example 1-1: Production of 3-(2,4-dichlorophenyl)-4-methyl-5-((l-ρhenylcyclopropane)-l- yl)- pyrazole [0123] l-(2,4-dichlorophenyl)-2-methyl-3-(l-phenylcyclopropane)-propane-l,3-dione (347 mg) were suspended in acetic acid (4 mL) and ethanol (2 mL), hydrazine hydrate (100 mg) was added and the mixture was heated for 3 hours at 80 °C. The reaction solution was concentrated and extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated brine, dried over anhydrous sodium sulfate, and concentrated to dryness. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:l) and dried to give the title compound (318 mg).
Figure imgf000023_0001
Examples 1-2 to 1-16: [0124] In the same manner as in Example 1-1, and using other conventional methods as necessary, a pyrazole compound was produced. The structural formula and property values of each Example compound are shown in the following Table.
Figure imgf000023_0002
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Experimental Example: in vitro HSDl (hydroxysteroid dehydrogenase 1) activity inhibitory action [0125] The HSDl inhibitory activity was examined by quantitative determination by an SPA (scintillation proximity assay) system of the suppressive action on the conversion from cortisone to cortisol using human HSDl (hereinafter recombinant HSDl) expressed using a baculo-virus system as an enzyme source. For the reaction, a reagent was added to a 96 well plate (96 well Opti-plates™-96 (Packard)) to the following final concentration and a volume of 100 μl was reacted at room temperature for 90 min. The reaction solution used was 0.1 μg/mL recombinant HSD 1 , 500 μM NADPH, 16 nM 3H cortisone (Amersham Biosciences, 1.78 Tbq/mol) dissolved in 0.1% BSA (Sigma)-containing PBS and the test drug was 2 μl of a compound solution (dissolved in DMSO). After 90 min, the reaction was stopped by adding PBS (40 μl, containing 0.1% BSA (Sigma)) containing 0.08 μg of anti-cortisol mouse monoclonal antibody (East Coast Biologies), 365 μg SPA PNT mouse antibody-binding beads (Amersham Biosciences) and 175 μM carbenoxolone (Sigma) to the reaction solution. After the completion of the reaction, the plate was incubated overnight at room temperature and the radioactivity was measured by Topcount (Packard). For control, the value (0% inhibition) of the well containing 2 μl of DMSO instead of the test drug was used, and for positive control, the value (100% inhibition) of the well containing carbenoxolone instead of the test drug at the final concentration of 50 μM was used. The inhibition (%) of the test drug was calculated by ((value of control - value of test drug)/(value of control - value of positive control)) x 100 (%). The IC50 value was analyzed using a computer-based curve fitting soft. The obtained results are shown in the following Table.
Figure imgf000027_0002
[0126] In the above Table, "+" in the column of IC50 means 1 OnM ≤ IC50<1 ,000nM and "++" in the column of IC50 means IC50 < lOnM.
Examples 2-1 to 2-45: [0127] In the same manner as in Example 1-1, and using other conventional methods as necessary, the pyrazole compounds shown in the following Table can be also produced.
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
[0128] As mentioned above, the pyrazole compound of the present invention has superior HSDl inhibitory activity and is useful as an HSDl inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity.

Claims

WHAT IS CLAIMED IS:
1. A pyrazole compound represented by the following formula:
Figure imgf000031_0001
wherein R1 is a hydrogen atom, -CO-O-alkyl, -COOH, an alkyl group, an alkoxy group or a cycloalkyl group, wherein the alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R10)(Rn), -N(R10)-CO-Rn, an aryl group and a heteroaryl group, wherein each R10 and R11 is independently a hydrogen atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group, wherein the subscript h is an integer of from 0 to 3, R12 and R13 in each instance are independently a hydrogen atom, an alkyl group or -CO-alkyl, and each R14 is independently -OH, an alkoxy group, an alkyl group or -N(R15)(R16), wherein R15 and R16 are each independently a hydrogen atom or an alkyl group; R2, R3, R4 and R5 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a cycloalkyl group or R2 and R3 in combination and R4 and R5 in combination with the carbon atoms to which they are attached, optionally form a ring represented by
Figure imgf000032_0001
wherein the Y1 ring is a cycloalkane or a heterocycloalkane, wherein the cycloalkane and the heterocycloalkane groups are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group, wherein the alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH , an alkoxy group, a cycloalkyl group, an alkenyl group,-COOH, -CO-O-alkyl, -CO-N(R10)(Rπ), an aryl group and a heteroaryl group, wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group;
the subscript n is an integer of from 0 to 3;
Ar1 is an aryl group or a heteroaryl group;
R6 and R7 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH2)j-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group or heteroaryl group wherein j is 0-3, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group; the subscript m is an integer of from 0 to 3;
R8 and R9 are each independently a hydrogen atom, a halogen atom, -OH, -NO2, -CN, an alkyl group, an alkoxy group, -CO-R17, -SO2-R17, -CO-N(R18)(R19), -N(R20)(R21) or in combination form -O-alkylene-O-, wherein the alkyl group and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O- alkyl, -CO-N(R10)(Rn), -N(R10)-CO-Rπ, an aryl group and a heteroaryl group, wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group, R17 is -OH, an alkoxy group, an alkyl group, -NH2, -NH-alkyl or -N(-alkyl)2, wherein the alkoxy group and alkyl groups are optionally substituted by substituents each independently selected from -OH, -SO2-R22 and -(CH2) -CO- R23, wherein t is 0-3, R22 is an alkyl group or -NH2, and R23 is an alkyl group, -NH-alkyl, -N(-alkyl)2, or -NH2, wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH2)U-N(R24)(R25) wherein u is 0-3, and R24 and R25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl R18 and R19 are each independently a hydrogen atom, an alkyl group or -(CH2)P-R26. wherein p is 0-3 and R26 is -OH, a haloalkyl group, an alkoxy group, -CO-NH2 or -N(R24)(R25), R20 and R21 are each independently a hydrogen atom, an alkyl group -CO-R23 or in combination with the nitrogen atom to which each is attached form
Figure imgf000034_0001
83 wherein the alkyl group is optionally substituted by substituents each 84 independently selected from -OH, -SO2-R22 and -(CH2)rCO-R23, X1 is -CO-, 85 -CH2- or -CH2-CH2-, X2 is -O-, -(CH2)q-, -N(R29)- or a spiro cyclic ring 86 represented by
Figure imgf000034_0002
88 wherein q is 0-2, R29 is a hydrogen atom, -CO-R30, -SO2-R30 or -(CH2)r-Ar3
89 wherein R30 is an alkyl group, an alkoxy group, -NH-alkyl or -N(-alkyl)2, 90 r is 0-3, and Ar3 is an aryl group or heteroaryl group,
91 wherein the aryl group and heteroaryl group are optionally substituted 92 by 1 to 3 substituents each independently selected from a halogen 93 atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), 94 -CN, -NO2, an alkoxy group, a cycloalkyl group, an alkenyl group, 95 -CO-R14, an aryl group and a heteroaryl group, and
96 the Y2 ring is spiro cycloalkyl or spiro heterocycloalkyl ring, and
97 R27 and R28 are each independently a hydrogen atom, a halogen atom, a haloalkyl 98 group, an alkyl group, -(CH2)h-OH, -N(R12)(R13), -CN, -NO2, an alkoxy group, a 99 cycloalkyl group, an alkenyl group, -CO-R14, an aryl group or a heteroaryl group;
100 Ar2 is an aryl group, a heteroaryl group or a ring having the formula
Figure imgf000034_0003
102 wherein V1 is CH or N, X3 is -(CH2)V-, 103 wherein v is 0-2, and
104 W1 is -C(R31)(R32)-, -CO- or -N(R33)-,
105 wherein R31 and R32 are each independently a hydrogen atom, an alkyl group,
106 an alkoxy group, a haloalkyl group, -(CH2)w-OH, -CO-R34, -L^Ar4 or
107 -N(R35)(R36),
108 wherein w is 0-3, R34 is -OH, an alkoxy group, an alkyl group or
109 -N(R37)(R38),
110 wherein R37 and R38 are each independently a hydrogen atom, an alkyl
111 group, -(CH2)x-OH or an alkoxy group,
112 wherein x is 0-3,
113 L1 is -(CH2)y-, -O- or -CO-,
114 wherein y is 0-3 ,
115 Ar4 is an aryl group or a heteroaryl group,
116 wherein the aryl group and the heteroaryl group are optionally
117 substituted by 1 to 3 substituents each independently selected from a
118 halogen atom, a haloalkyl group, an alkyl group, -(CH2)h-OH, -
119 N(R12)(R13), -CN, -NO2, an alkoxy group, a cycloalkyl group, an
120 alkenyl group, -CO-R14, an aryl group and a heteroaryl group, and
121 R35 and R36 are each independently a hydrogen atom, an alkyl group, -CO-
122 alkyl, -CO-O-alkyl or -L^Ar4, and
123 R33 is a hydrogen atom, -CO-R28, -SO2-R28 or -(CH2)k-Ar3,
124 wherein k is 0-3 ,
125 and the pyrazole ring labeled A, is selected from
Figure imgf000036_0001
127 a prodrug thereof or a pharmaceutically acceptable salt thereof.
1 2. The pyrazole compound of claim 1, where m is 0, a prodrug thereof or 2 a pharmaceutically acceptable salt thereof.
1 3. The pyrazole compound of claim 2, where R2 and R3 are in 2 combination with the carbon atom to which each is attached to form a ring represented by
Figure imgf000036_0002
4 wherein the Y1 ring is a C3-8 cycloalkane group, and the wavy lines indicate the point of 5 attachment to the remainder of the molecule.
1 4. The pyrazole compound of claim 3, where Ar1 is an phenyl group.
1 5. The pyrazole compound of claim 4, where R6 and R7 are each 2 independently a halogen atom or a hydrogen atom.
1 6. A pharmaceutical composition comprising the pyrazole compound of 2 claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a 3 pharmaceutically acceptable carrier.
1 7. A HSDl (1 l -hydroxysteroid dehydrogenase 1) inhibitor comprising 2 the pyrazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt 3 thereof as an effective component.
1 8. A therapeutic or prophylactic drug of diabetes, which comprises the 2 pyrazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt 3 thereof as an effective component.
9. A therapeutic or prophylactic drug of obesity, which comprises the pyrazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
10. A therapeutic or prophylactic drug of metabolic syndrome, which comprises the pyrazole compound of claim 1 , a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.
11. A method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of the pyrazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
12. A method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of the pyrazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
13. A method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of the pyrazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.
14. The method of claim 11, wherein a different therapeutic drug of diabetes is used in combination.
15. The method of claim 14, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an - glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer.
16. The method of claim 15, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
17. The method of claim 12, wherein a different therapeutic drug of diabetes is used in combination.
18. The method of claim 17, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, anc-- glucosidase inhibitor , a PTP1B inhibitor and an insulin sensitizer.
19. The method of claim 18, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
20. The method of claim 13, wherein a different therapeutic drug of diabetes is used in combination.
21. The method of claim 20, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an - glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer.
22. The method of claim 21, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.
23. The method of claim 11, wherein a different therapeutic drug of obesity is used in combination.
24. The method of claim 23, wherein the different therapeutic drug of obesity is Mazindol.
25. The method of claim 12, wherein a different therapeutic drug of obesity is used in combination.
26. The method of claim 25, wherein the different therapeutic drug of obesity is Mazindol.
27. The method of claim 13, wherein a different therapeutic drug of obesity is used in combination.
28. The method of claim 27, wherein the different therapeutic drug of obesity is Mazindol.
PCT/US2005/009292 2004-03-23 2005-03-21 Pyrazole compounds and uses related thereto WO2005095350A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005228856A AU2005228856C1 (en) 2004-03-23 2005-03-21 Pyrazole compounds and uses related thereto
CA002559945A CA2559945A1 (en) 2004-03-23 2005-03-21 Pyrazole compounds and uses related thereto
MXPA06010879A MXPA06010879A (en) 2004-03-23 2005-03-21 Pyrazole compounds and uses related thereto.
EP05733131A EP1735282A4 (en) 2004-03-23 2005-03-21 Pyrazole compounds and uses related thereto
JP2007505053A JP2007530549A (en) 2004-03-23 2005-03-21 Pyrazole compounds and related uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55601304P 2004-03-23 2004-03-23
US60/556,013 2004-03-23
US11/084,734 2005-03-18
US11/084,734 US7354938B2 (en) 2004-03-23 2005-03-18 Pyrazole compounds and uses related thereto

Publications (1)

Publication Number Publication Date
WO2005095350A1 true WO2005095350A1 (en) 2005-10-13

Family

ID=35063689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/009292 WO2005095350A1 (en) 2004-03-23 2005-03-21 Pyrazole compounds and uses related thereto

Country Status (7)

Country Link
US (2) US7354938B2 (en)
EP (1) EP1735282A4 (en)
JP (1) JP2007530549A (en)
AU (1) AU2005228856C1 (en)
CA (1) CA2559945A1 (en)
MX (1) MXPA06010879A (en)
WO (1) WO2005095350A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2007137066A2 (en) * 2006-05-17 2007-11-29 Incyte Corporation HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
WO2009020137A1 (en) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. Aminopyrazole amide derivative
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
US7659408B2 (en) 2003-08-07 2010-02-09 Merck Sharp & Dhome Corp. Pyrazole carboxamides as inhibitors of 11-β-hydroxysteroid dehydrogenase-1
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2008004100A3 (en) * 2006-07-05 2011-06-16 Pfizer Products Inc. Therapeutic compounds
US8324265B2 (en) 2005-11-21 2012-12-04 Shionogi & Co., Ltd. Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity
US8383622B2 (en) 2007-05-18 2013-02-26 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity
US8778925B2 (en) 2008-10-06 2014-07-15 Cancer Research Technology Ltd. Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer
WO2016055801A3 (en) * 2014-10-10 2016-06-30 Redag Crop Protection Ltd Agricultural chemicals
CN110636846A (en) * 2017-05-17 2019-12-31 艾库斯生物科学有限公司 Quinazoline pyrazole derivatives for the treatment of cancer related diseases
CN111704622A (en) * 2020-06-17 2020-09-25 中国科学院昆明植物研究所 Flavanol-menthane heterozygote, pharmaceutical composition thereof, preparation method and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680114A4 (en) * 2003-10-28 2008-09-24 Amgen Inc Triazole compounds and uses related thereto
CA2722427A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) * 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
JP2002193964A (en) 2000-12-22 2002-07-10 Sumitomo Pharmaceut Co Ltd Pyrazole derivative and its use in medicine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259316C (en) * 2001-04-05 2006-06-14 托伦脱药品有限公司 Heterocyclic compounds for aging-related and diabetic vascular complications
AR040241A1 (en) 2002-06-10 2005-03-23 Merck & Co Inc INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) * 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
JP2002193964A (en) 2000-12-22 2002-07-10 Sumitomo Pharmaceut Co Ltd Pyrazole derivative and its use in medicine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALMANSA ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 4, 1997, pages 547 - 558
See also references of EP1735282A4 *
SHEN ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 4, 2004, pages 935 - 940

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659408B2 (en) 2003-08-07 2010-02-09 Merck Sharp & Dhome Corp. Pyrazole carboxamides as inhibitors of 11-β-hydroxysteroid dehydrogenase-1
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US8324265B2 (en) 2005-11-21 2012-12-04 Shionogi & Co., Ltd. Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2007137066A2 (en) * 2006-05-17 2007-11-29 Incyte Corporation HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
WO2007137066A3 (en) * 2006-05-17 2008-07-03 Incyte Corp HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
US7838544B2 (en) 2006-05-17 2010-11-23 Incyte Corporation Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same
WO2008004100A3 (en) * 2006-07-05 2011-06-16 Pfizer Products Inc. Therapeutic compounds
US8383622B2 (en) 2007-05-18 2013-02-26 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity
WO2009020137A1 (en) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. Aminopyrazole amide derivative
US8778925B2 (en) 2008-10-06 2014-07-15 Cancer Research Technology Ltd. Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer
WO2016055801A3 (en) * 2014-10-10 2016-06-30 Redag Crop Protection Ltd Agricultural chemicals
CN110636846A (en) * 2017-05-17 2019-12-31 艾库斯生物科学有限公司 Quinazoline pyrazole derivatives for the treatment of cancer related diseases
CN110636846B (en) * 2017-05-17 2023-05-16 艾库斯生物科学有限公司 Quinazoline pyrazole derivatives for the treatment of cancer-related diseases
CN111704622A (en) * 2020-06-17 2020-09-25 中国科学院昆明植物研究所 Flavanol-menthane heterozygote, pharmaceutical composition thereof, preparation method and application thereof
CN111704622B (en) * 2020-06-17 2022-08-02 中国科学院昆明植物研究所 Flavanol-menthane heterozygote, pharmaceutical composition thereof, preparation method and application thereof

Also Published As

Publication number Publication date
US20050272793A1 (en) 2005-12-08
US7354938B2 (en) 2008-04-08
EP1735282A4 (en) 2010-03-17
CA2559945A1 (en) 2005-10-13
AU2005228856A1 (en) 2005-10-13
US20080161374A1 (en) 2008-07-03
MXPA06010879A (en) 2007-03-08
JP2007530549A (en) 2007-11-01
AU2005228856B2 (en) 2010-02-04
AU2005228856C1 (en) 2010-07-08
EP1735282A1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
EP1735282A1 (en) Pyrazole compounds and uses related thereto
US6511997B1 (en) Aminopyrazole derivatives
EP1680114A2 (en) Triazole compounds and uses related thereto
US9044469B2 (en) Opioid receptor ligands and methods of using and making same
EP3057962B1 (en) Hydrochloride salt form for ezh2 inhibition
PT1751131E (en) Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
WO1999062885A1 (en) Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
KR20080013944A (en) Cyclic amine derivative having substituted alkyl group
JP2004502760A (en) Pyrazole derivative
WO2006041119A1 (en) Hydrazide derivatives
TW201835072A (en) Novel cyp11a1 inhibitors
JP2001512103A (en) Heterocyclic derivatives inhibiting factor XA
HU202106B (en) Process for producing pharmaceutical compositions containing pyrazolin derivatives
KR20140140029A (en) Nipecotic acid derivative and use thereof for medical purposes
TWI242558B (en) PDE IV inhibiting pyridine derivatives
RU2384579C2 (en) Ortho-substituted aniline derivative and antioxidant medicinal agent
SG178043A1 (en) Substituted benzamide derivatives as glucokinase (gk) activators
CN113980001A (en) Pyrazole alcohol-pyridazinone coupling compound, pharmaceutical composition thereof and application thereof in medicines
TW201031659A (en) Novel compound having 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3H)-on structure and medicine containg same
EP2814814B1 (en) Imidazolylketone derivatives asd aldosterone synthase inhibitors
CN112480100B (en) Pyrrolidone derivatives
MXPA06004674A (en) Triazole compounds and uses related thereto
MXPA00011920A (en) Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2559945

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/010879

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007505053

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005733131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005228856

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005228856

Country of ref document: AU

Date of ref document: 20050321

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005228856

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005733131

Country of ref document: EP